Rate My Professor Timothy Mercer

Professor Timothy Mercer is Professor of Genomics at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at The University of Queensland, where he leads the Mercer Group as Group Leader and serves as Scientific Director of the BASE nucleic-acid synthesis facility. He completed his PhD in Genomics at The University of Queensland between 2004 and 2008, followed by postdoctoral research in transcriptomics, long-noncoding RNAs, and splicing at the Broad Institute in the United States, the Centre for Gene Regulation and Expression in Spain, and the Max Planck Institute for Cell Biology and Genetics in Germany. Prior to his current roles, Mercer was Group Leader at the Garvan Institute of Medical Research in Sydney, where he pioneered synthetic RNA and DNA controls to improve the accuracy of clinical genome sequencing and developed targeted RNA sequencing methods for diagnosing fusion genes in cancer patients. He also worked in Seattle on genome editing technologies during the early development of CRISPR and established Australia's RNA manufacturing capability as Director of the BASE facility in response to the COVID-19 pandemic.

Mercer's research specializes in genomics, transcriptomics, synthetic biology, and RNA regulation of the genome, with a focus on the expression and splicing of synthetic genes, bioinformatics, and genome biotechnologies such as mRNA production and quality analysis. During his PhD under Professor John Mattick at the Institute for Molecular Bioscience, he helped identify tens of thousands of new non-coding RNA genes and contributed to capture sequencing techniques that are now standard first-line diagnostics for fusion genes in cancer. His highly influential publications include 'Integrative analysis of 111 reference human epigenomes' (Nature, 2015, over 7,000 citations), 'Long non-coding RNAs: insights into functions' (Nature Reviews Genetics, 2009, over 6,600 citations), 'Long non-coding RNAs: definitions, functions, challenges and recommendations' (Nature Reviews Molecular Cell Biology, 2023), 'The role of testing during the COVID-19 pandemic' (Nature Reviews Genetics, 2021), and recent works on mRNA vaccine quality using RNA sequencing (Nature Communications, 2023) and rapid expression of therapeutic antibodies via mRNA transfection (mAbs, 2026). With more than 36,000 citations on Google Scholar, Mercer's contributions have advanced precision oncology, epigenetic regulation, and mRNA therapies.